Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir- based highly active antiretroviral therapy in patients with human immunodeficiency virus

Pharmacotherapy

Volumn 28, Issue 3, 2008, Pages 323-330

  Nguyen, Sean T ^a   Eaton, Susan A ^a   Bain, Amy M ^a,b   Rahman, Anita P ^a,b   Payne, Kenna D ^a,b   Bedimo, Roger ^b,c   Herrington, Jon D ^d   Maclayton, Darego O ^e,f   Rodriguez Barradas, Maria C ^f   Busti, Anthony J ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^e TEXAS SOUTHERN UNIVERSITY   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Atazanavir; Dyslipidemia; HIV; Human immunodeficiency virus; Protease inhibitor; Ritonavir

Indexed keywords

ATAZANAVIR; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; OMEGA 3 FATTY ACID; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTERY DISEASE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; JAUNDICE; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; SMOKING HABIT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; BODY WEIGHT; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES; RITONAVIR;

EID: 40149107019     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.3.323     Document Type: Article

References (41)

1. Tal A, Dall L. Didanosine-induced hypertriglyceridemia. Am J Med 1993;95:247.
2. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
3. Modest GA, Fuller J. Abacavir and diabetes. N Engl J Med 2001;344:142-4.
4. Schlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007;44:506-17.
5. Matthews G, Moyle G, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr 2000;24:310-15.
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
7. Dube M, Parker P, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18.
8. Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr 2005;38:236-8.
9. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. AIDS 1998;12:F51-8.
10. Echevarria KL, Hardin TC, Weiner M, Graybill JR. Serum lipids in patients infected with human immunodeficiency virus on protease inhibitor antiretrovirals. J Appl Ther Res 1999;2:171-6.
11. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
12. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, A Working Group of the Office of AIDS Research Advisory Council (ORAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (version 10/10/2006). Available from http://ADISinfo.nih.gov. Accessed February 3, 2007.
13. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9.
14. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
15. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Melab 1993;76:1423-7.
16. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700-5.
17. Constans J, Pellegrin JL, Peuchant E, at al. High plasma lipoprotein (a) in HIV-positive patients. Lancet 1993;341: 1099-100.
18. Stein J, Klein M, Bellehumeur J, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-62.
19. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary artery disease risk. Circulation 1990;82:495-506.
20. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse event associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet 2001;358:1322-7.
21. Tabib A, Greenland T, Mercier I, Loire R, Mornex JF. Coronary lesions in young HIV-positive patients at necropsy [letter]. Lancet 1992;340:730.
22. Capron L, Kim Y-U, Laurin C, Bruneval P, Fiessinger JN. Atheroembolism in HIV-positive individuals. Lancet 1992;340:1039-40.
23. Henry K, Melroe H, Huebsch J, Hermundson J, Simpson J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
24. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998;351:1958.
25. Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 1998;12:2079-80.
26. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors [letter]. Ann Intern Med 1999;131:548.
27. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
28. Fontas E, Van Leth F, Sabin A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-74.
29. Behrens G, Meyer-Olson D, Stoll M, Schmidt R. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003;17(suppl 1):S149-54.
30. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, for the Clincial Epidemilogy Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86.
31. Friis-Moller N, Reiss P, El-Sadr W, et al. Exposure to P1 and NNRT1 and risk of myocardial infarction: results from the D:A:D study Presented at the 13th conference on retrovirus and opportunistic infections, Denver, CO, February 5-8, 2006.
32. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27.
33. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174-80.
34. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-92.
35. McLaughlin C, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399-404.
36. Busti AJ, Bedimo R, Margolis D, Hardin D. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated patients after switch to atazanavir-ritonavir (ATV-RTV): a prospective study using hyperinsulinemic, euglycemic clamp testing [poster 57]. Poster presentation at the 8th international workshop on adverse drug interactions and lipodystrophy in HIV, San Francisco, September 24-26, 2006.
37. Carr A, Samaras K, Chisholm D, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;352: 1881-3.
38. Nolan D. Metabolic complications associated with protease inhibitor therapy. Drugs 2003;63:2555-74.
39. Cahn PE, Gatell JM, Squires K, et al. Atazanavir: a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients - results from two randomized clinical trials. J Int Assoc Physicians AIDS Care 2004;3:92-8.
40. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684-92.
41. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 2004;44;720-32.